Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Warsaw - Delayed Quote PLN

Molecure S.A. (MOC.WA)

Compare

9.05

0.00

(0.00%)

At close: 5:00:01 PM GMT+1

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for MOC.WA

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

96X.F FluoGuide A/S

3.7650

+0.27%

RGO.DU Regeneron Pharmaceuticals Inc

658.20

+0.12%

PH4.F CStone Pharmaceuticals

0.3720

0.00%

MAGLE.ST Magle Chemoswed Holding AB (publ)

32.60

-3.55%

600161.SS TIANTAN BIO

19.93

-0.60%

HQ1.MU Oruka Therapeutics Inc. R

10.60

0.00%

BSSP Baseline Productions, Inc.

0.0001

0.00%

GYX.F Futura Medical plc

0.1330

-24.86%

BXPHF Botanix Pharmaceuticals Limited

0.2650

-8.62%

10VA.F Immunic, Inc.

1.1250

-8.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Molecure S.A. (MOC.WA)

Comparisons

Indicators

Technicals

Corporate Events

-2.48%

-6.99%

-12.14%

-40.46%

-10.40%

-54.48%

-30.12%

-70.71%

Recent News: MOC.WA

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Related Tickers